FDA Flags Conflicts on 7-Peptide Panel as HHS Picks Members With Industry Ties
Updated
Updated · The Washington Post · Jul 17
FDA Flags Conflicts on 7-Peptide Panel as HHS Picks Members With Industry Ties
3 articles · Updated · The Washington Post · Jul 17
Summary
FDA officials warned that some candidates for next week’s peptide advisory panel posed conflict-of-interest risks, but HHS still selected multiple members tied to peptide clinics or sellers, according to people familiar with the process.
At least six recently added panelists have links to peptide-related businesses, and former FDA commissioner Marty Makary had already raised concerns internally before being told members would meet FDA ethics rules.
The July 23-24 panel will review whether compounding pharmacies should gain broader access to seven injectable peptides for conditions including obesity, insomnia and ulcerative colitis.
FDA career scientists said in briefing documents there is not enough evidence on the peptides’ safety and effectiveness, putting the agency’s staff analysis at odds with Health Secretary Robert F. Kennedy Jr.’s push to expand access.
Former FDA and HHS officials said HHS-driven selection of panelists is a significant break from the usual FDA-led process, fueling accusations that the administration is trying to stack the committee while staying within formal rules.